Siegfried’s Board of Directors and Executive Committee share the responsibility of steering the company towards our goals. Together, they uphold Siegfried’s values of excellence, passion, integrity, quality and sustainability, ensuring our continued success in a dynamic market.
Wolfgang Wienand (1972) joined the Siegfried Group in 2010 and was appointed CEO as of January 1, 2019. When joining Siegfried, Wolfgang first served as Chief Scientific Officer, responsible for Siegfried’s global Research & Development activities, before taking over the function as Chief Strategy Officer in December 2011 with responsibility for Strategy, Mergers & Acquisitions, Legal and Intellectual Property Management and Regulatory Affairs. From May 2017 until December 2018, he held in parallel both the Chief Scientific Officer and Chief Strategy Officer functions. Before joining Siegfried, Wolfgang held senior management positions at Evonik Industries AG (formerly Degussa AG) with a focus on fine chemical and custom development and manufacturing for the pharmaceutical industry.
Wolfgang Wienand is a member of the Board of Directors of Mettler-Toledo International Inc. and a member of the Supervisory Board of SCHOTT Pharma AG & Co. KGaA.
Wolfgang studied chemistry at the University of Bonn and obtained a Ph.D. in organic and bioorganic chemistry from the University of Cologne. In addition, he holds an Executive Master’s Degree in International Finance from École des hautes études commerciales HEC Paris. He is a German citizen.
Reto Suter (1971) joined Siegfried on May 1, 2017, as Chief Financial Officer, additionally responsible for Cyber Security and Risk Management. He is a member of the Board of Directors and Chairman of the Audit Committee of Inficon Holding AG. Over the last 16 years, he held a range of positions in industry as well as in finance and private equity. In his last function as COO, CIO and Board Member of Lonrho, a long-established company headquartered in London (UK) and Johannesburg (SA), Reto was responsible for overseeing the public takeover and subsequent delisting and restructuring.
Reto studied economics at the University of Zurich and the University of Washington in Seattle and completed his doctorate in banking and finance at the University of Zurich. He is a Swiss citizen.
Marcel Imwinkelried (1967) joined the Siegfried Group in January 2021 as Multi-Site Head for the Drug Products sites in Barberà del Vallès and El Masnou (Spain) as well as Irvine (California) and was appointed Chief Operating Officer Drug Products effective October 2021. Previously, he was with Novartis since 2005 in various roles with increasing responsibility and, from 2018, was appointed Global Head Technical Operations Solids.
Marcel graduated in mechanical engineering from the Lucerne University of Applied Sciences and holds a degree in business administration from the University of St. Gallen. He is a Swiss citizen.
Henrik Krüpper (1971) joined the Siegfried Group as of September 2023 as the Chief Operating Officer Drug Substances. Prior to joining Siegfried, he was the CEO of HCS Group, an international speciality chemicals company based in Germany, starting in 2019. His other roles within HCS Group since joining in 2012 included Managing Director and Chief Commercial Officer. He started his career at Th. Goldschmidt AG as Site Excellence and Production Manager followed by positions with increasing operational and managerial responsibilities at Evonik Industries AG (formerly Degussa AG), City Solar AG, Q-Cells SE and Soltecture GmbH.
Henrik holds a diploma (Dipl.-Ing.) in mechanical engineering with a specialization in process engineering from the Technical University (RWTH) Aachen in Germany. Henrik is a German citizen.
Jürgen Roos (1968) joined the Siegfried Group in April 2019 as Chief Scientific Officer. Before joining Siegfried, Jürgen worked for Evonik Industries AG as Vice President for Innovation Management of the Animal Nutrition business line. Jürgen started his professional career at Evonik (formerly Degussa-Hüls and Degussa AG) in 1999 as Laboratory Team Leader in chemical research in the field of fine chemicals. After various functions within the R&D organization of Evonik, including several years in Canada and the United Kingdom, he was appointed Head of Process Development in the field of exclusive synthesis in 2008, and subsequently took over the global responsibility for research and development of Evonik’s Health Care division. Jürgen is on the Board of Directors of the European Fine Chemicals Group (EFCG), the industry association of European fine chemical manufacturers, where he chairs the Innovation Committee.
Jürgen studied chemistry at the University of Stuttgart and obtained a Ph.D. in organic chemistry. He is a German citizen.
Marianne Späne (1962) joined the Siegfried Group in 2004 and was appointed Chief Business Officer in March 2010. She headed the Siegfried Generics Division from 2008 to 2010. From 2004 to 2008, Marianne managed the Business Development Department and the supply chain for generics. Previously, she was the Head of the Sales and Marketing department of the pharma division of Schweizerhalle. Subsequently, she joined Aceto, a US-based company, where she developed European expansion strategies. Prior to joining the pharmaceutical industry, she worked in logistics, business development and as site manager for Boucheron, a cosmetics company.
Marianne holds degrees in finance, business administration and marketing from the Business Management School (KFS) in Basel and the Marketing & Business School in Zurich (MBSZ). She is a German citizen.
Irene Wosgien (1973) joined the Siegfried Group as the Multi-Site Head for several drug substance sites in 2019, and was appointed Chief Human Resources Officer as of July 2023. Prior to her current role, she was Chief Operating Officer Drug Substances since January 2021. She has many years of experience in custom manufacturing in the pharmaceutical and food industry. Before joining Siegfried, Irene spent 15 years with the DSM group, in the Netherlands, holding various senior management positions, most recently as Vice President Operations Human Nutrition & Health.
Irene holds a Master’s degree in chemical engineering from Eindhoven University. She is a Dutch citizen.
Andreas Casutt (1963) joined the Board of Siegfried Holding AG in 2010 and was elected Chairman in 2014. He has been a partner at the law firm Niederer Kraft Frey AG in Zurich since 2002, and held office as managing partner from 2006 to 2014. Andreas specializes in corporate law, contract law, mergers & acquisitions, and stock exchange law. In addition, he is a board member of Mikron Holding AG, maxon international AG, Liechtenstein-based Bendura Bank AG and various privately held companies.
Andreas studied law and received his Ph.D. at the University of Zurich and completed an LL.M. program at the University of Michigan, Ann Arbor. He is a Swiss citizen.
Martin Schmid (1969) has been a member of Siegfried Holding AG’s Board of Directors since 2016. In 2011, he was elected State Councillor of the Canton of Graubünden. From 2003 to 2011, he was a member of the Canton of Graubünden government, where he headed the Department of Justice, Security and Health and subsequently the Department of Finance. Martin is an attorney-at-law. He is a member of the Board of Directors of Swiss Life Holding AG, Repower AG and holds various other directorships in the energy and construction sectors. He also chairs the Swiss Gas Industry Association (VSG ASIG), the Swiss Development Association, the Graubünden Cantonal Hospital Foundation and the Institute of Finance and Financial Law at the University of St. Gallen (IFF-HSG). He is also a member of the board of economiesuisse.
Martin studied law at the University of St. Gallen, where he received his doctorate in 2005. He is a Swiss citizen.
Alexandra Brand (1971) joined the Board of Siegfried Holding AG in 2022. Since 2015 she has held various senior management positions with Syngenta. In 2021, she was appointed Regional Director for EAME Crop Protection. In prior functions, she served as Syngenta’s Chief Sustainability Officer and as Regional Director, Europe, Africa & Middle East. Prior to joining Syngenta, Alexandra held various positions with increasing importance and responsibility with BASF for more than 15 years. In 2019, she was elected to the board of directors of Azelis, a PE-owned leading global distributor of specialty chemicals and food ingredients.
Alexandra studied Chemistry at the University of Darmstadt, where she also received her Ph.D. in inorganic chemistry. She is a German citizen.
Wolfram Carius (1961) joined the Board of Siegfried Holding AG in 2014. In October 2020 he was appointed Executive Vice President Pharmaceuticals heading the newly created Cell and Gene Therapy unit at Bayer. Prior, he served as Executive Vice President Pharmaceuticals Product Supply at Bayer and member of the Executive Committee at Bayer Pharma from September 2016. Previously, Wolfram worked for Sanofi, a French healthcare company, as Senior Vice President Biopharma Biologics and member of the Global Leadership Team. From 1987 to 2013, he held various positions with the pharma company Boehringer Ingelheim. In 2009, he was appointed to the company’s Board of Managing Directors, initially with responsibility for Human Resources and Technical Operations, and from 2012 for Biopharma and Operations. Before that, he was responsible for the development and expansion of the biopharma unit. He managed the company’s production site in Japan and worked later in Brazil as technical director before being appointed member of Boehringer Ingelheim’s Board of Managing Directors in Germany. Wolfram serves on the board of the privately held Uhlmann Group in Germany as well as on the boards of Südpack Medica AG and Ferring Ventures in Switzerland.
Wolfram holds a Ph.D. in Pharmaceutical Biology and Analytical Phytochemistry from the University of Saarland, Germany. In 2009, the Biberach University of Applied Sciences awarded him the title of honorary professor in recognition of his long and exceptional service. He is a German citizen.
Elodie Carr-Cingari (1974) was elected to the Board of Siegfried Holding AG in 2023. She has been the Chief Financial Officer of the Landis+Gyr Group since 2020. Previously, she held the position of Chief Financial Officer of the Hoerbiger Group. Prior to that, Elodie spent 11 years with Alstom and later, following the Alstom acquisition, General Electric, where she held several CFO positions of global businesses in the Energy and Grid sectors. She spent the first 10 years of her career with Hewlett-Packard where she held different finance leadership roles.
Elodie holds a Master of Business Administration from Bocconi University in Milan. She is a French and Swiss citizen.
Beat Walti (1968) joined the Board of Siegfried Holding AG in 2022. He has been a partner of Wenger Vieli, a Zurich-based law firm since 2007, specializing in commercial and corporate law and governance issues. From 1999 to 2013, Beat was a member of the Cantonal Council of Zürich. In 2014, he became a member of the Swiss National Council, where he is part of the Economic Affairs and Taxation Committee and also presided over the parliamentary group of “FDP/the liberals” from 2017 – 2022. Beat chairs the Foundation Board of the Ernst Göhner Foundation. He is a member of the board of DSV A/S in Denmark and holds various positions as chairman or member of the board of privately held companies and foundations. In addition, he is chairman of the board of OSPITA (Association of Swiss Enterprises in the Healthcare Sector) and member of the board of the Commercial Chamber of the Canton of Zürich and the advisory board of ExpertSuisse, the Swiss expert association for audit, tax and fiduciary.
Beat studied law at the Universities of Neuchâtel and Zurich and received his Ph.D. in 1998. He is a Swiss citizen.
Isabelle Welton (1963) was elected to the Board of Siegfried Holding AG in 2020. She is a proven leader with many years of experience in C-level functions of global corporations. She is the owner of a consulting firm specializing in corporate culture and change processes, Chairman of the NZZ media Group Board of Directors and a member of the Board of Directors of the Avobis Group. She is also a member of the boards of trustees of Swisscontact, SOS Kinderdorf Schweiz and Lucerne Festival. Before becoming self-employed, Isabelle was responsible for Human Resources and Corporate Culture at Zurich Insurance Group as a member of the Group Executive Board until 2017. Prior to that, she worked for IBM, where she held various positions in marketing and communications before taking over as Country General Manager of IBM Switzerland.
Isabelle holds a degree in law from the University of Zurich and has furthered her education at various universities in Australia and the USA. She is a Swiss citizen.
In order to strengthen the corporate governance of Siegfried, three committees support and advise the Board of Directors in the following areas: Audit, Remuneration and Strategy & Sustainability. The committees typically consist of three Board members with relevant experience in the committee’s field of responsibilities. Download the Organizational Regulations for more details on our committees.
The Audit Committee supports the Board of Directors in overseeing Siegfried’s financial integrity, internal controls, external audit, internal auditing, and financial risk management. Elodie Carr-Cingari is the Chairwoman and Dr. Martin Schmid and Dr. Wolfram Carius are members of the committee.
The Remuneration Committee advises the Board of Directors on compensation and other people-related matters, including remuneration strategy, policies and reports. Isabelle Welton is the Chairwoman and Dr. Martin Schmid and Dr. Beat Walti are members of the committee.
Strategy and Sustainability Committee
The Strategy and Sustainability Committee supports the Board of Directors in shaping Siegfried’s long-term strategic direction, corporate strategy, and sustainability efforts, including environmental, social, and governance matters. Dr. Wolfram Carius is the Chairman and Dr. Alexandra Brand and Dr. Beat Walti are members of the committee.